Table 3:
Regression
| Variable | β | t | p |
|---|---|---|---|
| Outcome: Dominant hand grip strength | |||
| Age | −.13 | −1.17 | .25 |
| Education | .22 | 1.91 | .06 |
| Time on any endocrine therapy (months) | .17 | 1.46 | .15 |
| Tamoxifen vs. Aromatase inhibitors | −.18 | −1.62 | .11 |
| Symptom Composite | −.27 | −2.42 | .02 |
| Outcome: Non-dominant hand grip strength | |||
| Age | −.27 | −2.40 | .02 |
| Education | .11 | 0.95 | .35 |
| Time on any endocrine therapy (months) | .11 | 0.93 | .36 |
| Tamoxifen vs. Aromatase inhibitors | −.01 | −0.07 | .94 |
| Symptom Composite | −.36 | −3.15 | .003 |
| Outcome: TUG | |||
| Age | .05 | 0.52 | .60 |
| Married | −.15 | −1.56 | .12 |
| Education | −.23 | −2.55 | .01 |
| Race (white=0; non-white=1) | .16 | 1.65 | .10 |
| ACE comorbidity scale | .23 | 2.26 | .03 |
| Symptom Composite | .18 | 1.97 | .05 |